Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.50
Bid: 5.32
Ask: 6.50
Change: -0.29 (-4.68%)
Spread: 1.18 (22.18%)
Open: 6.20
High: 6.50
Low: 6.20
Prev. Close: 6.20
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS SUMMARY: Angle revenue up; Synairgen, Bango loss widens

Thu, 29th Sep 2022 20:30

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Angle PLC - Surrey, England-based medical diagnostics company - Pretax loss in the first half of 2022 widens to GBP10.5 million from GBP8.7 million, due to "a planned investment." Revenue rises to GBP419,000 from GBP296,000, "driven by research use sales of the Parsortix system along with an initial contribution from the pharma services business, including both clinical trial services and bespoke assay development." Expects its first FDA clearance to "positively impact all areas" of its business going forward.

----------

Bango PLC - Cambridge-based mobile commerce company - Pretax loss widens to USD1.2 million in the first half of 2022 from USD617,000 a year before. Administrative expenses rise to USD10.4 million from USD9.2 million. Revenue grows to USD10.8 million versus USD9.9 million. Attributes this to its "virtuous circle strategy" and investment in research and development, which continues to generate strong growth. Believes it is well positioned to continue taking market share.

----------

XLMedia PLC - Henley-on-Thames-based digital publisher - Pretax loss widens to USD1.7 million in the first half of 2022 from USD439,000 a year ago. Sales and marketing costs jump to USD16.2 million from USD7.3 million. Revenue rises 48% to USD44.5 million from USD32.2 million. Attributes this to new partnerships throughout the period. Expects full-year adjusted earnings before interest, tax, depreciation, and amortization is broadly in line with the prior year, returning to growth in 2023.

----------

Maintel Holdings PLC - London-based cloud and managed service specialist - Pretax loss in the six months to June 30 dives to GBP575,000 from a profit of GBP3.8 million a year before. Revenue falls 13% to GBP46.7 million from GBP53.5 million. Blames this on hardware supply-chain problems that significantly hurt revenue. Notes that supply chains are not expected to normalise until the second quarter of 2023. Remains confident that it will return to organic growth as global supply chains normalise.

----------

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Pretax loss for the half-year to June 30 shrinks to GBP14.0 million from GBP38.9 million, as research and development expenditure falls to GBP11.1 million from GBP36.9 million. Explains that expenditure on the phase 3 Sprinter trial and manufacturing activities reduced.

----------

Armadale Capital PLC - London-based Africa-focused natural resource projects investor - Pretax loss in the first half of 2022 widens to GBP152,000 from GBP27,000 a year before. Records an unrepeated gain of GBP139,000 in the prior period.

----------

Arc Minerals Ltd - base metals exploration company focused in Africa - Pretax loss in the first half widens to GBP8.5 million from GBP3.6 million a year before. Attributes this to an expense of GBP6.8 million, due to the Zamsort/Handa restructuring, after transferring Zamsort assets and liabilities to Handa Resources Ltd.

----------

Orosur Mining Inc - Toronto-based mineral exploration & development company focused on South America - Net loss for continued operations in the year to May 31 narrows to USD1.4 million from USD1.7 million a year before. Gain on fair value of warrants increases to USD1.6 million from USD627,000. "The handing over of operational control at Anza in late 2021, and a strong balance sheet, have freed up our skilled South American team to examine investment in new projects. The addition of our Ariquemes tin project in Brazil, and of the El Pantano gold/silver project in Argentina have transformed the company into a well-balanced minerals exploration company," Executive Louis Castro comments.

----------

VPC Specialty Lending Investments PLC - invests in asset-backed loans to businesses originated by non-bank lenders - Net asset value as at June 30 falls to 105.51 pence from 114.14p as at December 31. Share price on the same date falls to 83.40p from 92.20p as at December 31. Delivers a total return of negative 4.1%. Blames this on an unpredictable and volatile macroeconomic environment. Declares quarterly dividends totalling 4.00 pence per share. Remains in a period of heightened uncertainty, with inflation still at "worryingly high levels".

----------

Crossword Cybersecurity PLC - Richmond, England-based cybersecurity solutions company - Pretax loss in the first half of 2022 widens to GBP2.3 million from GBP1.5 million a year before. Administrative expenses grow to GBP2.1 million from GBP1.5 million. Revenue grows 85% to GBP1.5 million versus GBP824,923. Attributes this to the integration of three companies with strong underlying Software as a service and services recurring revenue. Projects revenue growth of roughly 75% to GBP4 million in 2022, driven by organic growth and already completed acquisitions.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
5 Aug 2015 07:42

Synairgen Signs Research Collaboration Deal With Australia's Pharmaxis

Read more
22 Jul 2015 10:44

AstraZeneca starts next phase of testing on Synairgen asthma drug

(ShareCast News) - Synairgen announced AstraZeneca started another phase of testing on its asthma drug. AIM listed Synairgen said AstraZeneca begun its Phase IIa trial of the drug AZD9412 and expected results in early 2017. AstraZeneca would test 220 asthma patients whose conditions were exacerbate

Read more
22 Jul 2015 07:00

Synairgen Says AstraZeneca Begins Phase IIa Trial In Severe Asthma

Read more
22 Jun 2015 07:28

LONDON BRIEFING: Stocks Surge On Optimism For Greek Debt Deal

Read more
22 Jun 2015 05:13

AGM, EGM Calendar - Week Ahead

Read more
19 Jun 2015 15:14

AGM, EGM Calendar - Week Ahead

Read more
19 Jun 2015 05:21

AGM, EGM Calendar - Week Ahead

Read more
18 Jun 2015 15:06

AGM, EGM Calendar - Week Ahead

Read more
18 Jun 2015 05:27

AGM, EGM Calendar - Week Ahead

Read more
17 Jun 2015 14:56

AGM, EGM Calendar - Week Ahead

Read more
17 Jun 2015 05:23

AGM, EGM Calendar - Week Ahead

Read more
16 Jun 2015 15:03

AGM, EGM Calendar - Week Ahead

Read more
16 Jun 2015 05:23

AGM, EGM Calendar - Week Ahead

Read more
15 Jun 2015 14:52

AGM, EGM Calendar - Week Ahead

Read more
3 Mar 2015 08:38

Synairgen Swings To 2014 Pretax Profit On AstraZeneca Licence Deal

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.